Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07184385
PHASE3

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Sponsor: StemCyte, Inc.

View on ClinicalTrials.gov

Summary

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-03-31

Completion Date

2027-09-30

Last Updated

2025-09-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

REGENECYTE

HPC, Cord Blood

BIOLOGICAL

Placebo

Normal Saline